Bio Rad Laboratories Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 312.00.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Bio Rad Laboratories Inc's Score
Industry at a Glance
Industry Ranking
47 / 206
Overall Ranking
141 / 4490
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Bio Rad Laboratories Inc Highlights
StrengthsRisks
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 40.09, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 18.42M shares, decreasing 18.53% quarter-over-quarter.
Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.